Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
GlobeNewswire
· Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis..